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Abstract
Introduction: Preventive therapy is recommended in patients with migraines frequent and/or severe enough to interfere with daily life,
and/or with an inadequate response to acute therapy (26–43% of patients with migraine in a recent US survey). Preventive treatments
include beta blockers, amitriptyline, and antiepileptics (sodium valproate, gabapentin), but these may have significant adverse effects
and are contraindicated in some patients. Topiramate is an antiepileptic recently approved for prevention of migraine.
Aims: To assess the evidence on the therapeutic value of topiramate as preventive treatment for migraine in adults.
Evidence review: All identified outcomes were patient-oriented. Strong evidence shows that topiramate 100 or 200 mg/day is more
effective than placebo in reducing mean monthly migraine frequency, and further evidence shows better effectiveness than placebo on
responder rate, rescue medication use, migraine severity, and migraine duration. The 100 mg/day dose appears generally better
tolerated than 200 mg/day. Evidence shows that topiramate is associated with weight loss rather than weight gain. Limited evidence
suggests that topiramate can improve health-related quality of life and reduce days with disability. Uncontrolled studies indicate
effectiveness in refractory migraine. Limited evidence indicates broadly similar efficacy and tolerability for topiramate 100 mg/day and
propranolol 160 mg/day, though more comparative trials are required. There is insufficient economic evidence to assess the cost
effectiveness of topiramate.
Place in therapy: Topiramate 100 mg/day is the dose with the best balance between efficacy and tolerability, and offers therapeutic
value in patients in whom propranolol or other preventive migraine therapies are contraindicated, poorly tolerated, or ineffective.
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Core evidence place in therapy summary for topiramate in migraine prevention in adults
Outcome measure Evidence Implications
Patient-oriented evidence
Reduction in mean monthly migraine frequency and
% of responders
Clear Topiramate 100 or 200 mg/day is more effective than placebo
Reduction in mean monthly migraine days Clear Topiramate 100 or 200 mg/day is more effective than placebo
Reduction in need for acute migraine medication Clear Topiramate 100 or 200 mg/day is more effective than placebo
May reduce risk of medication overuse headache
Side effects: weight loss, paresthesia Clear Higher incidence with topiramate than placebo
Weight loss may be considered an advantage by some patients
Side effects: altered taste, anorexia, cognitive
difficulties, fatigue, nausea
Substantial Higher incidence with topiramate than placebo
Efficacy in refractory migraine Moderate Topiramate may be effective as add-on or monotherapy in some patients who have not
responded to other preventive drugs
Improved HRQOL Substantial Topiramate improves HRQOL more than placebo
Reduction in disability Moderate Greater reduction in days with disability with topiramate than placebo
Reduction in migraine duration and severity Moderate Shorter migraine duration and lower severity with topiramate than placebo
Improved MIDAS score Limited Topiramate improves MIDAS score from baseline
continued overleaf…Scope, aims, and objectives
Topiramate (Topamax®) was first developed for the treatment of
epilepsy, and in August 2004 was approved by the US Food and
Drug Administration (FDA) for the prophylaxis of migraine in adults.
This article reviews the evidence for the clinical use of topiramate
in the prevention of migraine in adults. Use in children and in the
acute treatment of migraine is not considered, as these are not
presently approved. Use in conditions other than migraine, such
as epilepsy, is outside the scope of this review.
Methods
Literature searches were conducted on February 9–17, 2005 in
the following databases, searching from the beginning of the
database to date unless otherwise stated. The search strategy
was “topiramate AND migraine” unless otherwise stated.
• Pub Med, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi, 1966
to date. Search strategy “(prevention OR prophylaxis OR
preventive OR prophylactic) AND migraine AND (topamax OR
topiramate)” limited to English-language results only, which
was expanded by Automatic Term Mapping to “((‘prevention
and control’[Subheading] OR prevention[Text Word]) OR
(‘prevention and control’[Subheading] OR prophylaxis[Text
Word]) OR preventive[All Fields] OR prophylactic[All Fields])
AND (‘migraine’[MeSH Terms] OR migraine[Text Word]) AND
((‘topiramate’[Substance Name] OR topamax[Text Word]) OR
(‘topiramate’[Substance Name] OR topiramate[Text Word]))
AND English[Lang]”
• EMBASE, http://www.datastarweb.com, 1974 to date. Search
strategy: “(prevention OR prophylaxis OR preventive OR
prophylactic) AND migraine AND (topamax OR topiramate)”
limited to English-language results only
• Database of Abstracts of Reviews of Effectiveness (DARE),
NHS Economic Evaluations Database (NHSEED), Health
Technology Assessment (HTA),
www.york.ac.uk/inst/crd/darehp.htm. All three databases were
searched together. All fields searched 
• NHS HTA, www.ncchta.org
• National Guideline Clearing House, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
www.cochrane.org/index0.htm. Entire site searched
• Clinical Evidence (BMJ), www.clinicalevidence.com
• www.clinicaltrials.gov
• www.clinicalstudyresults.org
Four sets of clinical guidelines were identified. After removal of
duplicates, a total of 142 records, excluding guidelines, were
identified from the search. Records were manually reviewed and
125 excluded for the following reasons: nonsystematic reviews
(n=71), studies in children (n=15), letters, editorials, news items,
comments and corrections (n=13), and articles that did not
investigate the clinical use of topiramate in migraine prevention
(n=26). A total of 17 remained and were included (Table 1). One
additional case report was identified, bringing the total to 18.
Meeting abstracts from 2002 or later were identified by searching
BIOSIS Previews, http://www.datastarweb.com, 1996 to date,
using the search strategy “(prevention OR prophylaxis OR
preventive OR prophylactic) AND migraine AND (topamax OR
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…table continued
Outcome measure Evidence Implications
Reduction in aura occurrence Limited Conflicting evidence on whether topiramate reduces the frequency of aura
Reduction in photophobia and phonophobia
symptoms
Limited Lower incidence with topiramate than placebo
Efficacy and tolerability compared with propranolol Limited Topiramate 100 mg/day similar to propranolol 160 mg/day
Patient acceptability and/or adherence compared
with other preventive migraine medications
No evidence
Economic evidence
Cost effectiveness compared with gabapentin Limited Better or similar CEN for topiramate 
Cost effectiveness compared with divalproex
sodium and metoprolol
Limited Poorer CEN for topiramate
Cost effectiveness compared with propranolol No evidence
Impact on indirect costs and use of healthcare
resources
Limited Additional costs of topiramate are partly offset by savings in indirect costs and the costs
of acute treatment
CEN, cost-equivalent number (number of migraines per month required for the savings in acute medication costs to outweigh the costs of preventive migraine therapy); HRQOL, health-related
quality of life; MIDAS, Migraine Disability Assessment questionnaire.105
topiramate) AND LG=EN AND PT=MEETING$ AND (YEAR=2002
OR YEAR=2003 OR YEAR=2004 OR YEAR=2005).” A total of 21
abstracts were retrieved, of which 13 were excluded for the
following reasons: studies in children (n=2), studies in animals
(n=2), studies in subjects without migraine (n=1), and duplicate
publications of data already presented in full papers (n=8). One
further abstract presented very limited information and appeared
to be probably an interim publication of a study published in full
elsewhere, although the amount of information was insufficient to
be certain, and this was also excluded. A total of seven were
included in the review (Table 1). 
The searches were updated on  June 28, 2005. A total of 40 new
records were identified, excluding duplicates. Of these, 38 were
excluded because they were animal studies (n=1), studies in
children (n=3), nonsystematic reviews (n=23), letters, notes or
editorials (n=8), or studies that did not investigate the clinical use
of topiramate in migraine prevention (n=3). The remaining two
were included (see Table 1). In addition, a further nine abstracts
not available on the databases searched were provided by the
manufacturer, Ortho McNeil (see Table 1).
For each outcome, preference was given to higher-level evidence
(level 1 and 2), with level 3 evidence also included where level 1
and/or 2 evidence was lacking or conflicting. Where outcomes
from level 2 or 3 studies were included in level 1 evidence, data
on these outcomes from the original studies were not considered
separately in this review.
Disease overview
Migraine is defined and classified according to criteria published
by the International Headache Society (IHS 2004). Several
subtypes are recognized, but the most common are migraine
without aura (formerly called common migraine) and migraine with
typical aura (formerly called classical migraine). The
characteristics of these types are summarized in Table 2. Chronic
migraine is defined as migraine occurring on at least 15 days per
month for over 3 months, not attributable to medication overuse
(IHS 2004). The term “transformed migraine” has been proposed
to describe headaches that originally presented as episodic
migraine and have changed over time into chronic daily headache
(very frequent or continuous headaches) (Nappi et al. 1999).
Burden of disease
Migraine is more common in women than men, affecting 18.2% of
women and 6.5% of men in a survey of over 29 000 people in the
US in 1999 (Lipton et al. 2001b). The prevalence was higher in
whites than in African-Americans and increased with declining
household income. In both sexes, the prevalence increased from
age 12 years (the youngest age group in the survey) to age 40 years
and then declined in older age groups (Lipton et al. 2001b). These
results mirrored those of an identical survey conducted in 1989,
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Number of records
Category Full papers Abstracts
Initial search 142 21
records excluded 125 14
records included 17 7
Additional studies identified 1 n/a
Search update, new records 40 0
records excluded 38 0
records included 2 0
Publications not available on
databases and supplied by
manufacturer
09
Level 1 clinical evidence (systematic
review, meta analysis)
1 0
Level 2 clinical evidence (RCT) 8 12
Level ≥3 clinical evidence 10 3
trials other than RCT 8 3
case reports 2 0
Economic evidence 1 1
Total records included 20 16
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review 
Migraine type Characteristics
Migraine
without aura
At least five attacks not attributed to another disorder and
fulfilling the following criteria:
• headache lasting 4–72 h if untreated or unsuccessfully
treated
• headache has at least two of the following features:
unilateral location; pulsating quality; moderate or severe
intensity; aggravation by, or causing avoidance of, 
routine physical activity (e.g. walking, climbing stairs)
• during headache at least one of the following is also
present: nausea and/or vomiting; photophobia and
phonophobia
Migraine with
typical aura
At least two attacks not attributed to another disorder and
fulfilling the following criteria:
• aura consisting of at least one of the following but
without motor weakness: fully reversible visual symptoms
(e.g. flickering lights, spots, or lines; loss of vision); fully
reversible sensory symptoms (e.g. pins and needles,
numbness); fully reversible dysphasic speech disturbance
• at least two of the following: homonymous visual
symptoms and/or unilateral sensory symptoms; at least
one aura symptom develops gradually over at least 5 min
and/or different aura symptoms occur in succession over
at least 5 min; each symptom lasts between 5 and 60 min
• headache fulfilling the criteria for “Migraine without aura”
begins during the aura or follows the aura within 60 min
Table 2 | Definition and classification of the main types of
migraine (adapted from IHS 2004)
 indicating that migraine prevalence and distribution have remained
stable over the period (Lipton et al. 2001b). Prevalence in other
Western countries is similar to that in the USA (Silberstein 2004).
Migraine frequently causes disability; 53% of the 1999 US survey
respondents reported that their headaches caused substantial
impairment in their activities, and 31% had missed at least 1 day
of work or school because of migraine in the last 3 months (Lipton
et al. 2001b). Patients with chronic migraine missed significantly
(P<0.05) more days of work, school, housework, leisure, or social
activities than patients with episodic migraine, and had
significantly (P<0.001) higher scores on the Migraine Disability
Assessment (MIDAS) questionnaire (higher MIDAS score
indicates greater impairment) (Bigal et al. 2003). 
Surveys in the US have shown that average total healthcare costs
were approximately 1.3 times higher for patients with self-
reported (Edmeads & Mackell 2002) or interview-ascertained
(Lafata et al. 2004) migraine than for people without migraine.
Retrospective claims data analysis has shown that families in
which one member has diagnosed migraine incur healthcare
costs up to 70% higher than in matched families with no migraine
(Stang et al. 2004). The total cost burden of migraine is substantial
(Table 3). As migraine is concentrated in adults of working age
and causes disability and/or impairment, the largest component
of cost is indirect cost (the cost of lost productivity due to
absence from work or reduced functional ability at work).
As well as the economic burden, migraine is also associated with
intangible burdens to patients. In a survey of over 5000 adults in
five countries, 34% of those with migraine considered that
migraine interfered considerably with their daily lives (Brandes
2002). Health-related quality of life (HRQOL) is substantially
impaired in patients with migraine. In a case–control study in 200
migraine patients and 200 matched controls in the UK, the
migraine patients scored significantly lower than the controls in
eight of nine domains on the Medical Outcomes Study Short
Form 36 (SF-36), a well-established general instrument for
measuring HRQOL (Lipton et al. 2003). Similar results were
reported from a study in 84 migraine patients in Italy, where all
domains of the SF-36 were statistically (P<0.001) and clinically
(>5 points) worse in the migraine patients than in the general
Italian population (Bussone et al. 2004).
Pathophysiology of migraine
The causes and pathophysiology of migraine are incompletely
understood (Bussone 2004). Various factors may trigger migraine
attacks in individual patients, including missing meals, bright
lights and loud noise, changes in sleep patterns, unaccustomed
strenuous exercise, estrogen levels (this may contribute to the
higher prevalence of migraine in women between the ages of
puberty and menopause, compared with older women and men),
and dietary items such as certain alcoholic drinks and citrus fruits
(BASH 2004). Overuse of medications for acute headache (ergots,
triptans, and analgesics) may also cause chronic headaches
(BASH 2004), and it is recommended that acute medication use
should be restricted to 2–3 days per week to avoid this
(Silberstein 2004).
Migraine was once thought to be a vascular disease because of
the throbbing nature of the pain, with the aura caused by cerebral
vasoconstriction and the headache caused by reactive
vasodilation (Silberstein 2004). However, more recent data have
shown that cerebral blood flow is often reduced when the
headache begins (Olesen et al. 1990), and migraine is now
thought to be caused by neuronal dysfunction (Bussone 2004;
Silberstein 2004). The migraine aura is thought to be produced by
a neurologic phenomenon called cortical spreading depression, a
decrease in electrical activity that spreads across the cerebral
cortex at a rate of 2–3 mm/min (Silberstein 2004). Magnetic
resonance imaging studies of patients with migraine have shown
that the migraine aura is accompanied by a spreading change in
blood oxygenation in the visual cortex, consistent with a decrease
in cortical blood flow resulting from fluctuations in neuronal
activity (Hadjikhani et al. 2001). In animal models, blockade of
calcium channel conduction (Richter et al. 2002) or N-methyl-D-
aspartate glutamate receptors (Anderson & Andrew 2002) have
been shown to inhibit cortical spreading depression. The release
of potassium, nitric oxide, and other agents stimulates trigeminal
sensory nerve endings on cortical blood vessels, which in turn
activates the trigeminal nucleus in the brainstem. Neurons from
the trigeminal nucleus release neuropeptides such as substance
P and calcitonin-gene-related peptide (CGRP) in the meninges
(the membranes surrounding the brain), producing meningeal
vasodilation and neurogenic inflammation. The neurogenic
inflammation sensitizes nerve endings, so that normal stimuli
(such as blood vessel pulsations) now trigger nerve impulses,
thus causing (in part) the pain of a migraine headache (Silberstein
2004).
Antimigraine drugs may interfere with these processes in a
variety of ways, as reviewed by Silberstein (2004). For example,
ergots and triptans act on 5-HT1B and 5-HT1D receptors to
constrict extracerebral intracranial blood vessels, inhibit
trigeminal neurons, and block transmission in the trigeminal
nucleus (Silberstein 2004). The mechanism of action of
topiramate in migraine is not well understood, but it has several
actions that may be relevant. Topiramate inhibits sodium ion
channels and may thus limit the repetitive firing ability of
neurons (Taverna et al. 1999), it reduces the activity of L-type
calcium channels (Zhang et al. 2000), it is a negative modulator
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Country Cost of migraine per year Reference
Direct Indirect Total
France €1044 million NR NR Pradalier et
al. 2004
Spain €344 million €732 million €1076 million Badia et al.
2004
USA $US1 billion $US13 billion $US14 billion Hu et al.
1999
NR, not reported.
Costs are given in the original currency. The average exchange rate in 2004 was
€1 = $US1.24 (source: www.fxtop.com)
Table 3 | Cost burden of migraine
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of glutamate transmission (Skradski & White 2000), and it
enhances neurotransmission mediated by gamma-amino-
butyric acid (GABA) (White et al. 2000). In animal models GABA
agonists can suppress activity of neuronal pain pathways in the
trigeminal nucleus (Storer et al. 2004). Topiramate is also a weak
inhibitor of carbonic anhydrase, though it is not known whether
this action contributes to its effects in migraine and epilepsy
(Cutrer 2001).
Current therapy options
Treatment guidelines from the USA and Europe recommend
broadly similar therapeutic options for migraine management
(Silberstein 2000; Snow et al. 2002; BASH 2004; Géraud et al.
2004) (Table 4). Topiramate was approved by the FDA for
prevention of migraine in adults in August 2004 (Anon. 2004),
and thus had not been approved when the two sets of US
guidelines were published. As this review is concerned with 
the use of topiramate in migraine prevention, acute therapies 
are outside the scope of the article and are summarized only
very briefly.
There is debate over the most effective treatment strategy in
acute migraine. Some practitioners advocate stepped care, where
patients are treated first with the safest and cheapest therapy
known to have efficacy (simple oral analgesics with or without
antiemetics), and if this fails to work treatment is stepped up to
specific antimigraine therapy (triptans or ergots). Others suggest
using a stratified care model, which categorizes patients into
severity classes at the beginning of treatment and selects
treatment accordingly. One study has reported that a stratified
care strategy, in which patients with lower migraine severity
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BASH 2004 Géraud et al. 2004 Silberstein 2000
(US Headache Consortium)a
Snow et al. 2002
(AAFP/ACP-ASIM)b
Acute
treatment
Simple analgesics with or without
antiemetics
Triptans
Ergotamine
NSAIDs alone or with
metoclopramide
Triptans
Ergotamine
Triptans
Analgesics
Metoclopramide
Ergotamine
NSAIDs
Triptans
Dihydroergotamine
Criteria for
preventive
migraine
treatment
Inadequate symptom control with
acute therapy
Over-frequent use of acute therapy
Severe, frequent and/or disabling
migraine
In patients taking 6–8 doses of
acute medication per month for
≥3 months
Frequent headaches that interfere
with daily life
Contraindication, failure, overuse
or intolerance of acute treatments
Patient preference and cost
Uncommon types of migraine
2 or more attacks per month
producing 3 or more days of
disability per month
Contraindication, failure or overuse
of acute treatments
Uncommon types of migraine
Preventive treatment
First-line Beta blockers without partial
agonist activity (atenolol,
metoprolol, propranolol)
Amitriptyline
Propranolol, metoprolol
Oxeterone
Amitriptyline
Amitriptyline
Divalproex sodium
c
Propranolol, timolol
Propranolol, timolol
Amitriptyline
Divalproex sodium, sodium
valproate
Second-line Sodium valproate
Topiramate
Pizotifen
Flunarizine
Sodium valproate
Gabapentin
Topiramate
Atenolol, metoprolol, nadolol
Calcium channel blockers
(verapamil, nimodipine)
NSAIDs
Fluoxetine
Gabapentin
Feverfew, magnesium, vitamin B2
Flunarizine
Lisuride
Pizotifen
Time-released dihydroergotamine
Methysergide
Third-line Gabapentin
Methysergide
Methysergide Antidepressants
Cyproheptadine
Diltiazem
Ibuprofen
Topiramate
Phenelzine
Methysergide
aThese guidelines classified medication into Group 1 (proven high efficacy and mild–moderate adverse events), Group 2 (lower efficacy and mild–moderate adverse events), Group 3 (use based
on opinion), and Group 4 (proven efficacy but frequent or severe adverse events). Group 1 is listed here as first-line, group 2 as second-line, and groups 3 and 4 as third-line.
bThese guidelines classified medication into first-line agents and “other agents with proven efficacy but frequent or severe adverse events or limited published data on adverse events” (listed
here as second-line).
cDivalproex sodium (also called valproate semisodium) is a complex of sodium valproate and valproic acid in a 1:1 ratio.
AAFP, American Academy of Family Physicians; ACP-ASIM, American College of Physicians–American Society of Internal Medicine; BASH, British Association for Study of Headache; NSAID,
nonsteroidal antiinflammatory drug.
Table 4 | Current therapy options recommended in migraine treatment guidelines
 received nonsteroidal antiinflammatory drugs (NSAIDs) plus
metoclopramide while patients with higher migraine severity
received a triptan, was more effective and cost effective than
stepped care (Von Seggern 2002). However, the BASH (2004)
guidelines recommend a stepped care model for acute treatment,
and other guidelines consider that it is not yet clear which is the
most effective approach (Snow et al. 2002).
Treatment guidelines recommend broadly similar criteria for
determining whether patients should be offered preventive
treatment for migraine (Table 4). A questionnaire survey of 77 879
households in the USA found that 11.7% of respondents met
clinical criteria for migraine, of whom 26–43% would be eligible
for preventive treatment (Silberstein et al. 2005a). The US
Headache Consortium guidelines (Silberstein 2000)
recommended the following goals for preventive treatment of
migraine:
• reduce attack frequency, severity, and duration
• improve responsiveness to treatment of acute attacks
• improve function and reduce disability.
Treatment guidelines have grouped preventive drugs into
categories based on available evidence for their effectiveness and
tolerability. The exact methods and definitions vary, but there is a
considerable degree of agreement (see Table 4). In general, the
preferred agents are amitriptyline, propranolol, and divalproex
sodium (also called valproate semisodium). Table 5 presents
summary information on the efficacy and tolerability of some
migraine prophylactic drugs.
There is uncertainty over the optimal duration of migraine
preventive therapy, although treatment guidelines generally
recommend that an attempt should be made to taper or
discontinue preventive treatment (Evans 2004). The BASH 2004
guidelines recommend that an attempt should be made to
withdraw preventive therapy after 4–6 months of effectiveness to
test continued need, and that uninterrupted treatment for very
long periods is rarely appropriate (BASH 2004).
Treatment of migraine in special patient groups
Women with menstrual migraine can generally be managed in the
same way as patients with nonmenstrual migraine (Landy 2004).
Migraine improves during pregnancy in 50–80% of patients,
possibly due to the increased level of estrogen, but attacks
continue in some patients (Gladstone et al. 2004). First-line acute
therapy in pregnant women is acetaminophen (paracetamol) and
antiemetics if required, and other analgesics may be used with
caution (Gladstone et al. 2004). Triptans are categorized as FDA
category C (no risk in humans has been proved, but cannot be
ruled out), while ergots are contraindicated (Landy 2004).
Preventive therapy should be avoided in pregnant women, but
some category C medications (propranolol, amitriptyline,
verapamil, topiramate) may be used when the benefit outweighs
the risk (Gladstone et al. 2004).
Treatment in elderly patients may be challenging due to the
presence of concomitant medical conditions, polypharmacy, and
age-related changes in drug distribution, elimination, and
metabolism that increase the risk of adverse effects (Gladstone et
al. 2004). First-line acute therapy options include acetaminophen
and NSAIDs, but these should be used with caution because of
the risks of gastrointestinal bleeding and renal or hepatic
insufficiency. Triptans are contraindicated in patients with a
history of, or risk factors for, cardiovascular, cerebrovascular, and
peripheral vascular disease (Gladstone et al. 2004). Preventive
options are limited because of contraindications (see Table 5) and
side effects. Cognitive and sedative side effects may be
particularly problematic in elderly patients and may occur with
propranolol, tricyclic antidepressants (e.g. amitriptyline), valproic
acid, gabapentin, and topiramate (Gladstone et al. 2004).
Unmet needs
Despite the availability of treatment guidelines, current treatment
of migraine is not optimal. Migraine is underdiagnosed, as
reported by a survey in 1999 of over 3000 patients in the US who
met IHS criteria for migraine, only 48% of whom had received a
physician diagnosis of migraine (Lipton et al. 2001a). This had
improved since an identical survey carried out 10 years earlier,
when the proportion was only 38%, but indicates that half of
patients with migraine are still not diagnosed. One reason for the
low diagnosis rate may be that many patients with migraine do
not consult a doctor. In a survey of over 5000 adults in five
countries, consultation rates for patients with headache varied
from 41% in the USA to 63% in France (Brandes 2002). 
Satisfaction with migraine treatment is poor. Among 516 patients
with clinically diagnosed migraine in five countries, only 27%
considered that their current medication was consistently
effective, and only 36% were “very satisfied” with their therapy
(Brandes 2002). In a survey of 22 patients with migraine
requesting advice on treatment from a community pharmacy in
Chicago, 46% of patients were dissatisfied with their current
migraine therapy, and 91% wished they could prevent their
headaches (Wenzel et al. 2004).
Current preventive migraine therapies have significant
disadvantages. Only about half to two-thirds of patients respond
to treatment (see Table 5). Some patients may fail to respond to
numerous preventive treatments; one trial of 69 patients with
refractory migraine reported that the median number of previously
failed therapies was nine (Von Seggern et al. 2002). There is little
information on the relative efficacy of migraine preventive
therapies. Many of the established drugs in migraine prophylaxis
have been in use for many years (e.g. propranolol, amitriptyline),
and comparative trials conducted to modern methodologic
standards are few. A recent systematic review of propranolol in
migraine prevention found that “the methodological quality of the
majority of trials was unsatisfactory” (Linde & Rossnagel 2004).
This review concluded that propranolol was more effective than
placebo and as effective as calcium channel blockers, other beta
blockers and a variety of other drugs including amitriptyline,
methysergide, and divalproex sodium, although the authors
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commented that “sample size was insufficient in most trials to
establish equivalence” (Linde & Rossnagel 2004). Treatment
guidelines typically categorize preventive migraine drugs
according to the amount of evidence supporting their efficacy and
the frequency and severity of side effects (see Table 4), rather than
on the basis of relative efficacy. This suggests that efficacy is
considered to be broadly similar for current preventive migraine
drugs, and that treatment choice among those agents with
evidence of efficacy may be guided by adverse events,
contraindications, and/or patient preference. Uptake of preventive
migraine drugs is low. For example, in Sweden less than 10% of
patients with migraine who consult a physician use preventive
therapy, although more than 50% would be eligible (C. Dahlöf,
personal communication). Similarly, in the US a survey of 77 789
households identified 19 018 individuals with migraine, and found
that of those who would be eligible for preventive therapy only
20% were receiving it (Lipton et al. 2005).  There is a need for
improved therapies with better efficacy and, if possible, improved
overall tolerability. 
Some preventive agents are contraindicated in patients with
certain comorbid conditions, limiting potential treatment
options in these individuals (see Table 5; Silberstein 2004).
Patients may also discontinue therapy because of side effects
they find distressing or intolerable. Weight gain has been
reported as a particular issue in patient satisfaction with
headache drugs (Young & Rozen 2004), and a cause of
discontinuation of therapy with amitriptyline (Von Seggern
2002) and valproate (Young & Rozen 2004). This may reflect the
preponderance of migraine in adult women, in whom weight
gain may be an especially undesirable effect (Von Seggern
2002). Valproate is also associated with gastrointestinal side
effects (e.g. nausea, vomiting, dyspepsia), asthenia,
drowsiness, tremor, and hair loss, although it has little effect on
cognitive function (Krymchantowski et al. 2002). Gabapentin is
associated with asthenia, dizziness, and somnolence, but has
advantages over valproate in that it is free from some disturbing
adverse events such as weight gain, tremor, and hair loss
(Krymchantowski et al. 2002). 
The major areas where a new treatment could offer valuable
improvements over current therapies are:
• improved effectiveness (particularly in patients with refractory
migraine that does not respond to current therapies)
• reduced incidence of side effects that patients find distressing
and that may provoke treatment discontinuation
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Drug Effectiveness Adverse effects Contraindications Reference
Divalproex
sodium/sodium
valproate
a
Divalproex sodium responders to
treatment
b 148/352 (42%)
Sodium valproate responders to
treatment
b 17/34 (50%)
Clinical impression of effect
c +++
Occasional to frequent Liver disease, bleeding disorders Chronicle & Mulleners 2004;
Silberstein 2000, 2004
Gabapentin Responders to treatmentb 26/56
(46%)
Clinical impression of effect
c ++
Occasional to frequent Liver disease, bleeding disorders Chronicle & Mulleners 2004;
Silberstein 2000, 2004
Carbamazepine Responders to treatmentb 26/45
(58%)
Clinical impression of effect
c 0
Occasional to frequent Chronicle & Mulleners 2004;
Silberstein 2000
Topiramate Responders to treatmentb 132/264
(50%)
Clinical impression of effect
c ++
Occasional to frequent Kidney stones Chronicle & Mulleners 2004;
Silberstein 2000, 2004
Propranolol Responders to treatmentd 77/114
(68%)
Clinical impression of effect
c +++
Infrequent to occasional
Dropout rate due to AEs
e
9/193 (4.7%)
Asthma, depression, congestive
heart failure, Raynaud’s disease,
diabetes
Linde & Rossnagel 2004;
Silberstein 2000, 2004
Amitriptyline Clinical impression of effect
c +++ Frequent Mania, urinary retention, heart
block
Silberstein 2000, 2004
Naproxen/
naproxen
sodium
Clinical impression of effect
c + Infrequent Ulcer disease, gastritis Silberstein 2000, 2004 
aDivalproex sodium (also called valproate semisodium) is a complex of sodium valproate and valproic acid in a 1:1 ratio.
bDefined as patients with a 50% or greater reduction in migraine frequency compared with baseline. Number of events (patients who responded) and total number of patients presented in
original source (Chronicle & Mulleners 2004).
cDefinitions as follows: 0, most people get no improvement; +, few people get clinically significant improvement; ++, some people get clinically significant improvement; +++, most people get
clinically significant improvement.
dDefinition of response varied among the pooled trials. Data given here are for propranolol 160 mg/day. Number of events (patients who responded) and total number of patients presented in
original source (Linde & Rossnagel 2004).
eData given here are for propranolol 160 mg/day. Number of events (patients who dropped out due to AEs) and total number of patients presented in original source (Linde & Rossnagel 2004).
AE, adverse event.
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Level of
evidence
Design Treatment and
target dose
[median dose]
Outcome Reference
Migraine frequency (mean no. of
attacks/month)
% responders
1 Systematic review
and meta analysis
of 3 RCTs
Placebo
T 50 mg/day 
T 100 mg/day 
T 200 mg/day
Lower with T 100 mg or 200 mg vs
placebo (P<0.0001)
Lower with T 100 mg or 200 mg vs T 
50 mg (P<0.05)
NSD T 50 mg vs placebo
NSD T 100 mg vs 200 mg
More responders with T 50 mg, 100 mg
or 200 mg vs placebo (P<0.001)
More responders with T 100 mg or 
200 mg vs T 50 mg (P<0.01)
NSD T 100 mg vs 200 mg
Chronicle &
Mulleners 2004
a
2 Double-blind
multicenter RCT, 
12 weeks
maintenance
Placebo (n=73)
T 200 mg/day 
[135 mg/day
b]
(n=138)
NSD T vs placebo in ITT analysis
In subgroup of patients with migraine
with aura (approx. 1/3 of total), decrease
from baseline with T (P=0.018)
NR Freitag 2003
2 Pooled analysis of 
2 double-blind
single-center RCTs,
8–12 weeks
maintenance
Placebo (n=36)
T 200 mg/day (n=34)
Lower with T vs placebo (P=0.001) More responders with T vs placebo
(P=0.008)
Edwards et al.
2003
2 Multicenter RCT, 
7 weeks double-
blind followed by 
11 weeks open-label
Placebo (n=115)
T 50 mg/day (n=117)
T 100 mg/day
(n=125)
T 200 mg/day
(n=112)
c
Greater decrease with T 100 mg or
200 mg vs placebo (P<0.001)
NSD T 50 mg vs placebo
23% placebo
35% T 50 mg
54% T 100 mg
52% T 200 mg
d
Silberstein 2003
2 Double-blind single-
center RCT,
12 weeks
maintenance
Placebo (n=37) 
T 100 mg/day
(n=35)
e
Greater decrease with T vs placebo
(P<0.001)
More responders with T vs placebo
(P<0.01)
Mei et al. 2004
2 Double-blind RCT,
20 weeks, followed
by open-label
extension,
56 weeks, n=29
total
T for 76 weeks of
treatment
Placebo for 20
weeks then T for
56 weeks
Mean T dose during
open-label phase,
127 mg/day
Significant reduction in both groups
(P<0.01)
NR Hart et al. 2002
2 Double-blind
multicenter RCT,
18 weeks
maintenance
Placebo (n=143)
T 100 mg/day
[87.9 mg/day] (n=139)
T 200 mg/day
[124.2 mg/day]
(n=143)
Propranolol 160
[129.6 mg/day]
mg/day (n=143)
Greater decrease with T 100 mg vs
placebo (P=0.011)
NSD T 200 mg vs placebo
Similar decrease for T 100 mg and
propranolol
f
More responders with T 100 mg or
200 mg vs placebo (P<0.05)
Similar for T 100 mg or 200 mg and
propranololf
Diener et al. 2004
aThe three trials included were Brandes et al. 2004, Silberstein et al. 2004, and Storey et al. 2001.
bMean dose.
cPatient numbers unclear in the original as the numbers given in the figures (given here) do not match the numbers given in the text.
dNo between-group comparison reported.
ePatients who completed the trial.
fNo between-group P value reported, but 95% confidence intervals for the difference between topiramate and propranolol included zero, indicating comparable results.
ITT, intention-to-treat; NR, not reported; NSD, not statistically significantly different; RCT, randomized controlled trial; T, topiramate.
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• fewer contraindications, allowing use in patients with common
comorbid conditions (e.g. asthma, diabetes) in whom one or
more of the current first-line preventive treatments are
contraindicated.
Important outcome measures include the number of headache
episodes per month, the number of headache days per month,
HRQOL, and overall tolerability.
Clinical evidence with topiramate
As pain and aura are subjective symptoms, migraine outcomes
rely on the patient’s report and/or grading of symptoms. The most
commonly measured outcomes in the published evidence are
concerned specifically with migraine symptoms, e.g. recording
the presence or absence of migraine in a diary (from which the
frequency of migraine attacks in a given period may be
calculated), recording the presence of aura symptoms, recording
the duration of each migraine attack, or categorizing the severity
of the migraine attack on a scale such as mild, moderate, or
severe. Others, less commonly measured, estimate the broader
effect of migraine on the patient’s life by recording disability or
HRQOL. Even the outcomes concerned specifically with migraine
have an obvious benefit to the patient; for example, it is clearly
better to have fewer migraine attacks in a month, or for the
attacks to be shorter or less painful when they occur. Thus, all the
outcomes covered by the evidence reviewed in this section can
be considered patient-oriented outcomes.
Outcomes where individual symptoms are not specified, such as
reduction in migraine frequency, responder rate, migraine
duration, and migraine severity, refer to a migraine attack as
classified by the patient’s own judgment.
Most trials titrated the dose of study drug(s) over a period of
several weeks aiming to reach a specified target dose, then
continued at the dose reached for a maintenance period. The
dose groups are normally referred to in the study publications by
the target dosage, and the same convention is followed in this
review. Where the original publication also gave the median or
mean dose actually reached, this is noted in the data tables
(Tables 6–10).
Reduction in migraine frequency
The reduction in mean number of migraine attacks per month was
the primary efficacy endpoint in most trials, and therefore the
measure on which they were powered. Strong evidence from a
systematic review and meta analysis and three further
randomized controlled trials (RCTs) indicated that topiramate was
more effective than placebo in reducing mean monthly migraine
frequency at target doses of either 100 mg/day or 200 mg/day
(Table 6). One study failed to find a difference between topiramate
200 mg/day and placebo in the main intention-to-treat (ITT)
analysis (Freitag 2003), but this study is difficult to evaluate as it
was presented only in the form of conference proceedings and
very little detail was given. Another study (Diener et al. 2004) failed
to find a statistically significant difference between topiramate
200 mg/day and placebo, but as the same study found that
topiramate 100 mg/day was significantly more effective than
placebo this may represent an aberrant result. The study authors
consider that it was probably due to a high early dropout rate
(mainly due to adverse events) in the topiramate 200 mg/day
group (Diener et al. 2004).
In the trials which included a 50-mg target dose, it was found to be
not statistically significantly different from placebo in reducing
mean monthly migraine frequency. The systematic review and
meta analysis compared the topiramate doses and found that both
100 mg/day and 200 mg/day were significantly more effective than
50 mg/day, but there was no significant difference between
100 mg/day and 200 mg/day (see Table 6). Taken together, the
evidence indicates that topiramate was equally effective at either
100 mg/day or 200 mg/day, but not at 50 mg/day.
Only one published trial included an active control, propranolol
160 mg/day (Diener et al. 2004). This trial was primarily designed
and powered to compare topiramate with placebo rather than
topiramate with propranolol, and no P values were presented for
comparisons between topiramate and propranolol. However,
95% confidence intervals (CI) calculated for the difference in
mean monthly migraine frequency between topiramate
100 mg/day and propranolol 160 mg/day indicated similar
efficacy. More comparative trials are required to further assess the
relative efficacy of the two agents.
Evidence from open-label extension periods following two
double-blind clinical trials indicates that topiramate remained
effective on this outcome measure in long-term treatment (up to 8
months) (Rapoport et al. 2005). After the end of the double-blind
phase, a total of 567 patients entered the extension and received
open-label topiramate, titrated according to clinical need up to a
maximum of 1600 mg/day (mean dose 124.7 mg/day and
150.3 mg/day for patients who had received placebo or
topiramate, respectively). After 8 months’ open-label treatment,
the mean monthly migraine frequency was 2.2 among patients
who had previously received topiramate (compared with 3.4 at the
end of the double-blind phase) and 3 among patients who had
previously received placebo (compared with 4.9 at the end of the
double-blind phase) (Rapoport et al. 2005).
Onset of action
In some trials, migraine frequency was recorded at several time
points during the study period, allowing a time course to be
plotted. The onset of drug action was considered to be the first
time point at which there was a statistically significant difference
from placebo.
Two large multicenter RCTs (Brandes et al. 2004; Silberstein et al.
2004) both reported that topiramate 100 mg/day and 200 mg/day
reduced mean monthly migraine frequency significantly (P<0.05)
more than placebo at the first time point, which was 1 month into
the titration period, and maintained a statistically significant
difference throughout the study. This was supported by results
from a single-center RCT, which reported a statistically significant
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Level of
evidence
Design Treatment and target
dose [median dose]
Outcome Reference
Migraine
days/month
Rescue medication
days
Migraine duration Migraine severity
2 Double-blind,
multicenter
RCT, 18 weeks
maintenance
Placebo (n=114)
T 50 mg/day [46.5
mg/day] (n=117)
T 100 mg/day [85.6
mg/day] (n=120)
T 200 mg/day [150.2
mg/day] (n=117)
Greater decrease
from baseline with T
100 mg or 200 mg
vs placebo (P<0.01)
NSD T 50 mg vs
placebo
Greater decrease
from baseline with T
100 mg or 200 mg
vs placebo (P<0.05)
NSD T 50 mg vs
placebo
Greater decrease
from baseline with T
200 mg vs placebo
(P=0.007)
NSD T 50 mg or 100
mg vs placebo
Lower with T 100 mg
vs placebo (P=0.04)
NSD T 50 mg or 200
mg vs placebo
Brandes et
al. 2004
2 Double-blind,
multicenter
RCT, 18 weeks
maintenance
Placebo (n=115)
T 50 mg/day [44.7
mg/day
a] (n=117)
T 100 mg/day [78.3
mg/day
a] (n=125)
T 200 mg/day [116.2
mg/day
a] (n=112)
Greater decrease
from baseline with T
100 mg or 200 mg
vs placebo (P<0.001)
NSD T 50 mg vs
placebo
Greater decrease
from baseline with T
100 mg or 200 mg
vs placebo (P<0.01)
NSD T 50 mg vs
placebo
NR NR Silberstein et
al. 2004
2 Double-blind
multicenter
RCT, 12 weeks
maintenance
Placebo (n=73)
T 200 mg/day [135
mg/day
a] (n=138)
Decrease from
baseline with T
(P=0.016)b
NSD T vs placebo Decrease 30% with
T
Increase 30% with
placebo
b
Decrease 7% with T
Decrease 0.5% with
placebob
Freitag 2003
2 Multicenter
RCT, 7 weeks
double-blind
followed by
11 weeks
open-label
Placebo (n=115)
T 50 mg/day (n=117)
T 100 mg/day (n=125)
T 200 mg/day (n=112)c
Greater decrease
from baseline for T
100 mg or 200 mg
vs placebo (P<0.01)
NR NR NR Silberstein
2003
2 Double-blind
single-center
RCT, 12 weeks
maintenance
Placebo (n=37) 
T 100 mg/day (n=35)
d
NR Greater decrease
from baseline with T
vs placebo (P<0.001)
NR NR Mei et al.
2004
2 Double-blind,
single-center
RCT, 8 weeks
maintenance
Placebo (n=21)
T 200 mg/day [125
mg/day
a] (n=19)
NR NR NR NSD T vs placebo Storey et al.
2001
2 Double-blind
multicenter
RCT, 18 weeks
maintenance
Placebo (n=143)
T 100 mg/day [87.9
mg/day] (n=139)
T 200 mg/day [124.2
mg/day] (n=143)
Propranolol 160 [129.6
mg/day] mg/day
(n=143)
Greater decrease
with T 100 mg vs
placebo (P=0.026)
NSD T 200 mg vs
placebo
Similar decrease for
T 100 mg or 200 mg
and propranolol
e
Greater decrease
with T 100 mg vs
placebo (P=0.029)
NSD T 200 mg vs
placebo
Similar decrease for
T 100 mg and
propranolol
e
Decrease from
baseline 0.8 days for
T 100 mg, 0.6 days
for T 200 mg, 0.4
days for placebo
b
NR for propranolol
NR Diener et al.
2004
continued opposite…
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difference in mean monthly migraine frequency between
topiramate 100 mg/day and placebo at the end of the 4-week
titration period (Mei et al. 2004). 
A further large multicenter RCT with propranolol as an active
control found that both topiramate 100 mg/day and propranolol
160 mg/day reduced mean monthly migraine frequency
significantly more than placebo (P<0.05) at the first time point
(1 month into the titration period) (Diener et al. 2004). Thus, the
available evidence shows that topiramate has an onset of action
of approximately 1 month, similar to that of propranolol.
Responder rate
The evidence also demonstrates a similar pattern for responder
rate (the percentage of patients who experienced at least a 50%
reduction in the mean frequency of migraine attacks). Topiramate
100 mg and 200 mg appear to be equally effective and more
effective than either placebo or topiramate 50 mg, although on
this outcome measure topiramate 50 mg was also more effective
than placebo (see Table 6). 
As with the data on reduction in migraine frequency, there were no
comparative data on responder rates between different agents.
One trial that included propranolol as an active control reported
similar effects for propranolol 160 mg/day and topiramate 100 or
200 mg/day (Diener et al. 2004).
Although the 50% threshold is the most widely used definition
of response, there is limited evidence (two level 3 studies) of
topiramate’s effects on response rate defined by more 
stringent criteria. In a telephone survey of 102 patients with
migraine or transformed migraine who were using low-dose
topiramate (up to 50 mg/day), 66% reported an improvement of
at least 75% in headache frequency, and 11 patients became
headache-free (Kowacs et al. 2003). An observational study in
Spain in 115 patients with refractory migraine (no response 
to, or intolerant of, beta blockers, amitriptyline, flunarizine,
and/or valproate) reported that 34 patients (29%) experienced
a reduction in headache frequency of >75% after 3 months 
of treatment with topiramate (median dose 100 mg/day)
(Pascual et al. 2003).
Number of migraine days/month 
There is strong evidence from three RCTs that topiramate
100 mg/day and 200 mg/day reduced the mean number of
migraine days per month statistically significantly more 
than placebo, although topiramate 50 mg/day was not
significantly better than placebo (Table 7). One trial reported that
topiramate 100 mg/day was superior to placebo but topiramate
200 mg was not, but this paradoxical result may reflect the high
dropout rate in the topiramate 200 mg/day group in that study
(Diener et al. 2004). 
The effect of topiramate 100 mg or 200 mg on this outcome
measure was similar to that of propranolol in the one study
with an active control, although the study was not
designed to compare the two agents (see Table 7; Diener
et al. 2004).
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Level of
evidence
Design Treatment and target
dose [median dose]
Outcome Reference
Migraine
days/month
Rescue
medication days
Migraine duration Migraine severity
3 Open survey,
mean
treatment
duration
7 months
T up to 50 mg/day (n=102) NR NR NR Reduction in % of
patients reporting
intense headaches
(from 88% to 18%)
Kowacs et
al. 2003
3 Open
longitudinal
study,
6 months
T 100 mg/day (n=12)
Results after
6 months T treatment
compared vs baseline
NR NR 62% patients
reported shorter
headache duration
with T
Lower during T
treatment (P<0.001)
Lampl et al.
2004
3 Retrospective
case series,
mean
treatment
duration
149 days 
T mean dose 208 mg/day
(n=74)
Topiramate treatment
period compared with
previous treatment
Lower during T
treatment
(P<0.0001)
74% patients
reported using less
rescue medication
during T treatment
45–58% patients
reported shorter
headache duration
during T treatment
Lower during T
treatment (P<0.001)
Young et al.
2002
aMean dose.
bNo between-group statistical comparison presented.
cPatient numbers unclear in the original as the numbers given in the figures (given here) do not match the numbers given in the text.
dPatients who completed the trial.
eNo between-group P value reported, but 95% confidence intervals for the difference between topiramate and propranolol included zero, indicating comparable results.
NR, not reported; NSD, not statistically significantly different; RCT, randomized controlled trial; T, topiramate.Rescue medication use
Evidence from two large RCTs showed that topiramate 100 mg/day
and 200 mg/day were both effective in reducing the use of rescue
medication (medication used to treat acute migraine attacks)
compared with placebo, while topiramate 50 mg/day was not (see
Table 7). One study (Freitag 2003) reported no statistically
significant difference between topiramate 200 mg/day and
placebo, but this study reported results only in a small subgroup of
patients who had migraine with aura and was published only as a
conference proceedings paper with limited detail. The study of
Diener et al. (2004) again found a paradoxical result that topiramate
100 mg/day was statistically significantly more effective than
placebo but that topiramate 200 mg/day was not, which may have
been due to a high rate of early withdrawals due to adverse events.
In the one study that used propranolol as an active control, the
effects of topiramate 100 mg/day were reported to be similar to
propranolol (see Table 7).
Migraine duration 
There is evidence from one large RCT that topiramate 200 mg/day
significantly reduced mean migraine duration compared with
placebo, while topiramate 100 mg/day and 50 mg/day did not (see
Table 7). Two other RCTs reported that headache duration was
shorter in patients receiving topiramate than placebo, or that the
mean duration decreased with topiramate but not with placebo, but
neither presented a test of statistical significance (see Table 7). In
addition, two single-group open-label studies found that around
half the patients reported a reduction in headache duration during
topiramate treatment compared with the period before topiramate
treatment (see Table 7). This evidence suggests that topiramate can
reduce mean migraine duration, particularly at higher doses.
Migraine severity
One large RCT reported that topiramate 100 mg/day was
associated with a significant reduction in mean migraine severity
score compared with placebo, but no statistically significant
difference was found for topiramate 200 mg/day or 50 mg/day (see
Table 7). A further RCT reported a greater percentage decrease in
severity score for topiramate compared with placebo, but this was
in a small subgroup of patients who had migraine with aura and no
statistical test was reported (Freitag 2003). A small RCT found no
statistically significant difference between topiramate and placebo,
but this study involved only 40 patients (Storey et al. 2001). All three
level 3 studies reported a decrease in mean migraine severity or in
the percentage of patients with severe headaches after patients
began topiramate treatment (see Table 7). Taken together, the
evidence indicates that topiramate can improve migraine severity,
but the dose–response relationship is not clear.
Number of days with disability
Topiramate 100 mg/day was associated with a statistically
significant (P<0.01) reduction from baseline in the mean number of
days with disability due to migraine after 8, 12, and 16 weeks of
treatment in the one study reporting data on this outcome measure
(Mei et al. 2004; level 2 evidence). In the month before the trial, the
mean number of days with disability was 6.8 in the topiramate
group, and after 16 weeks of treatment this had declined by around
4.2 days. The placebo group had a similar baseline number of days
with disability (6.95 days/month), and after 16 weeks this had
declined by approximately 1 day. No statistical comparison between
the topiramate and placebo groups was reported (Mei et al. 2004).
MIDAS score
An open-label study (level 3 evidence) in 26 patients with migraine
taking either topiramate 100 mg/day (n=23) or 200 mg/day (n=2)
for prophylaxis with a 12-week maintenance phase reported that
mean MIDAS score improved from 3.47 before treatment to 1.6 at
the end of the treatment period (no statistical comparison
reported) (Dolezil et al. 2003).
A retrospective chart study (level 3 evidence) reported data on
MIDAS scores in 96 patients with transformed migraine treated
with topiramate up to 200 mg/day as adjunctive therapy (Mathew
et al. 2002). The mean MIDAS score was 90.2 before treatment
and improved significantly to 24.9 after treatment (P<0.0001)
(Mathew et al. 2002).
Frequency of aura
Topiramate did not statistically significantly reduce either the
frequency or duration of migraine aura in an open-label study
(level 3 evidence) of 12 patients with migraine with aura treated
with topiramate 100 mg/day for 6 months (Lampl et al. 2004). A
conference proceedings paper on a study of topiramate in 211
patients with migraine, of whom “almost one-third” had migraine
with aura, commented that “patients with aura showed a marked
reduction in the incidence of aura from baseline” (Freitag 2003),
but no further details were provided. A post-hoc pooled analysis
of patients with migraine with aura enrolled in three double-blind
clinical trials reported that topiramate (target dose 100 mg/day)
reduced the mean monthly frequency of aura significantly more
than placebo (P=0.020) (Silberstein et al. 2005b). 
Frequency of photophobia and phonophobia
A report of conference proceedings describing a subgroup of
patients with migraine with aura enrolled in a double-blind
placebo-controlled trial (“almost one-third” of 211 patients)
(Freitag 2003) reported that topiramate treatment was associated
with a significantly greater reduction in the occurrence of
photophobia compared with placebo (41% reduction vs 15%
reduction,  P=0.02). Topiramate also reduced phonophobia
symptoms by 40%, but the difference from placebo was not
statistically significant (Freitag 2003).
Patient global evaluation
A retrospective chart study (level 3 evidence) reported data on
96 patients with transformed migraine taking topiramate up to
200 mg/day as adjunctive therapy and 70 patients with episodic
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migraine taking topiramate as monotherapy (Mathew et al.
2002). Patients were asked to evaluate the overall effectiveness
of their treatment at clinic visits. Among the patients with
transformed migraine, 27% rated topiramate as having
produced a marked improvement and a further 27% as
moderate improvement. Among the patients with episodic
migraine, the corresponding values were 61% and 17%
(Mathew et al. 2002).
Health-related quality of life
A double-blind, placebo-controlled clinical trial (Brandes et al.
2004) measured HRQOL and these results were presented
separately in abstract form (Diamond et al. 2003). HRQOL was
measured with a widely used generic measure, the SF-36, and
a disease-specific measure, the Migraine-Specific Quality-of-
Life questionnaire (MSQ). Topiramate 50 mg, 100 mg, or
200 mg improved the MSQ Role-Restrictive and Role-
Preventive subscales significantly more than placebo
(P≤0.019). Topiramate 100 mg or 200 mg also improved the
MSQ Emotional Function subscale (P<0.001) and the SF-36
Role-Physical subscale (P≤0.022) significantly more than
placebo (Diamond et al. 2003). A similar analysis of a second
double-blind placebo-controlled trial (Silberstein et al. 2004)
reported that topiramate 100 mg/day significantly improved
HRQOL, though no quantitative data were presented in the
abstract (Dahlöf et al. 2003).
Further evidence comes from pooled analyses of all three large
double-blind topiramate studies (Brandes et al. 2004; Diener et al.
2004; Silberstein et al. 2004). In the intent-to-treat population,
topiramate 100 mg (n=372) improved all three of the MSQ
subscale scores significantly (P<0.001) more than placebo
(n=362) (Dahlöf et al. 2005). Similar results were reported in
another analysis with slightly fewer patients included (topiramate
100 mg, n=358; placebo, n=347) (Diamond et al. 2005a).
Another pooled analysis of data from the same three studies,
also in the intent-to-treat population but with 384 patients in
the topiramate 100 mg group and 372 in the placebo group,
investigated the effect on SF-36 score. This analysis found that
topiramate 100 mg improved the SF-36 Physical Component
Score significantly more than placebo (P<0.001) (Diamond et al.
2005b). Subgroup analysis showed that patients who
responded to treatment with topiramate 100 mg (defined as a
reduction of at least 50% in mean monthly migraine frequency
at end of treatment compared with baseline) had significantly
greater improvements on all three MSQ subscale scores
(P<0.001) and on the SF-36 Physical Component Score
(P<0.001) and the SF-36 Mental Component Score (P=0.026)
compared with patients who did not respond to treatment
(Diamond et al. 2005c).
Tolerability
Evidence on the reported incidence of adverse events is
presented in Table 8. Paresthesia appears clearly linked to
topiramate use; the systematic review reported number-needed-
to-harm (NNH)1 values of 2.3 and 2.4 for the topiramate
200 mg/day and 100 mg/day doses, respectively, and the
incidence in the topiramate groups in the other trials ranged up
to 65%, compared with 6–22% in the placebo groups and 12%
for propranolol in the one trial using this drug. As with the other
adverse events, statistical tests of the difference in incidence
between groups were not presented. There appeared to be little
difference in incidence between topiramate 100 mg and 200 mg
in trials containing both doses. Altered taste also seems clearly
linked to topiramate, although fewer trials reported data. The
NNH values were 6.7–11.8, and the incidence was noticeably
higher than for placebo or propranolol where comparative data
were presented.
Cognitive problems and anorexia appeared to be more common at
the 200 mg/day dose than at the 100 mg/day dose, though both
doses appeared to show a higher incidence than placebo or
propranolol. Anorexia is likely to be linked to topiramate’s effects on
weight loss (see separate section below). Fatigue appeared to occur
somewhat more commonly with topiramate than placebo, perhaps
especially at the 200 mg dose, and also occurred at a similar rate
with propranolol. Few trials reported data on nausea, although the
limited evidence suggests that its incidence was higher at the
200 mg dose than the 100 mg dose, both were higher than placebo,
and the 100 mg dose was similar to propranolol (see Table 8).
Withdrawal rates due to adverse events also appeared to show a
dose-related pattern, with withdrawal rates for 100 mg and
200 mg topiramate higher than for placebo, 200 mg higher than
100 mg, and 100 mg similar to propranolol (see Table 8). A
pooled analysis of data from patients in four double-blind
placebo-controlled trials (topiramate 100 mg, n=386; placebo,
n=445) reported that the most common topiramate-associated
adverse events of paresthesia, fatigue, and anorexia all occurred
more frequently during the titration period than during the
maintenance period (Freitag et al. 2005).
In summary, the evidence indicates that paresthesia, altered
taste, anorexia, and cognitive problems may be associated with
topiramate. The 100 mg/day dose appears better tolerated than
the 200 mg/day dose overall. The authors of the trial using
propranolol as an active control concluded that the tolerability
profile of topiramate 100 mg/day was comparable to that of
propranolol 160 mg/day (Diener et al. 2004), although as the trial
was not powered to compare topiramate and propranolol more
evidence is needed to confirm this.
A case of psychosis, manifested as auditory hallucinations, after
2 days of treatment with topiramate 25 mg twice daily for
migraine prophylaxis has been reported in a 28-year-old woman
with a history of bipolar-type schizoaffective disorder and
migraine without aura, with no history of seizures (Matthews &
Miller 2001). Two days after discontinuing topiramate, the
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1The reciprocal of the absolute difference in risk between the
active treatment group and the placebo group. The smaller the
NNH, the higher the risk of the adverse event in the active
treatment group relative to the placebo group.
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Level of
evidence
Design Treatment
and target
dose
[median dose]
Outcome Reference
Paresthesia Anorexia Fatigue Nausea Altered taste Cognitive
difficultya
Withdrawals
due to AEs
1 Systematic
review and
meta analysis
of 3 RCTs
Placebo
T 50 mg/day
T 100 mg/day
T 200 mg/day
NNH:
T 50 mg: 3.4
T 100 mg:
2.4
T 200 mg:
2.3
NNH:
T 50 mg:
30.5
T 100 mg:
14.4
T 200 mg:
11.3
NNH:
T 50 mg:
22.3
T 100 mg:
32.9
T 200 mg:
12.1
NNH:
T 50 mg:
undefined
T 100 mg: 29
T 200 mg:
19.2
NNH:
T 50 mg: 6.9
T 100 mg:
11.8
T 200 mg:
6.7
NNH:
T 50 mg:
19.7
T 100 mg:
14.1
T 200 mg:
7.7
T 50 mg:
17%
T 100 mg:
19–26%
T 200 mg:
11–32%
Chronicle &
Mulleners
2004
b
2 Double-blind
multicenter
RCT, 12
weeks
maintenance
Placebo
(n=73)
T 200 mg/day
[135 mg/day
c]
(n=138)
d
T: 43%
Placebo: NR
NR T: 24%
Placebo: NR
NR NR NR 4 patients
(total number
of patients
NR)
Freitag
2003
2 Pooled
analysis of
2 double-
blind single
center RCTs,
8–12 weeks
maintenance
Placebo
(n=36)
T 200 mg/day
(n=34)
T: 65%
Placebo: 22%
T: 12%
Placebo: 6%
NR NR T: 32%
Placebo: 3%
T: 18%
Placebo: 6%
T: 6/34
Placebo:
0/36
Edwards et
al. 2003
2 Multicenter
RCT, 7 weeks
double-blind
followed by
11 weeks
open-label
Placebo
(n=115)
T 50 mg/day
(n=117)
T 100 mg/day
(n=125)
T 200 mg/day
(n=112)
e
NR
5% of
patients with
paresthesia
stopped
treatment as
a result
NR NR NR NR Withdrawal:
T 100: 2%
T 200: 2%
NR Silberstein
2003
2 Double-blind
single-center
RCT, 12
weeks
maintenance
Placebo
(n=37) 
T 100 mg/day
(n=35)
f
T: 23%
Placebo: 6%
NR T: 11%
Placebo: 0
NR T: 6%
Placebo: 0
T: 8%
Placebo: 0
T: 17/58
P: 2/57
Mei et al.
2004
2 Double-blind
multicenter
RCT, 18
weeks
maintenance
Placebo
(n=143)
T 100 mg/day
[87.9 mg/day]
(n=139)
T 200 mg/day
[124.2
mg/day]
(n=143)
Propranolol
160
[129.6 mg/day]
mg/day
(n=143)
T 100: 55%
T 200: 56%
Propranolol:
12%
Placebo: 6%
T 100: 17%
T 200: 14%
Propranolol:
3%
Placebo: 6%
T 100: 19%
T 200: 24%
Propranolol:
22%
Placebo:
15%
T 100: 13%
T 200: 17%
Propranolol:
13%
Placebo: 8%
T 100: 5%
T 200: 14%
Propranolol:
0
Placebo: 1%
T 100: 9%
T 200: 15%
Propranolol:
5%
Placebo: 4%
T 100:
37/141
T 200:
63/144
Propranolol:
29/144
Placebo:
15/146
Diener et
al. 2004
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patient’s mental state returned to baseline. The authors comment
that an association between psychosis and epilepsy is well
established, and suggest that topiramate may be associated with
development of psychotic symptoms via poorly understood
effects on neurotransmitter systems (Matthews & Miller 2001).
However, this appears to be an isolated case.
A case report from India described the occurrence of acute
myopia and elevated intra-ocular pressure leading to temporary
loss of vision in a 40-year old woman with migraine, 4 days after
beginning treatment with topiramate 25 mg/day and flunarizine
5 mg/day (Bhattacharyya & Basu 2005). Topiramate was
immediately withdrawn and diuretics begun to reduce the intra-
ocular pressure, and the patient’s visual acuity returned to 
normal on the 5th day (Bhattacharyya & Basu 2005). Other 
cases of acute glaucoma with topiramate have been reported
(Fraunfelder et al. 2004), and the potential occurrence of 
this adverse reaction is noted in the prescribing information 
(Anon 2005a) and on the manufacturer’s website
(http://www.topamax.com/utilities/safety_info.jsp).
Weight loss
Strong evidence shows that topiramate is associated with weight
loss (Table 9). Typically, mean weight loss in the groups taking
topiramate 100 mg/day or 200 mg/day was around 2–3 kg or
3–4% of body weight at baseline. The reported percentage of
patients with weight loss varied considerably between the
studies. However, this may reflect differences in the definition of
weight loss between the studies; there was insufficient
information presented to assess this point further.
Economic evidence
One study published as a full paper has investigated the cost
effectiveness of topiramate (Adelman et al. 2002). This study
used data on reduction in mean monthly migraine frequency
from published clinical trials combined with US drug prices to
estimate the monthly costs of preventive therapy with
topiramate 200 mg/day, gabapentin, divalproex sodium, and
metoprolol, and the number of migraines per month required for
the savings in acute medication costs to offset preventive
medication costs. The efficacy data for topiramate 200 mg/day
were taken from the study of Edwards et al. (2003). 
For each preventive treatment, the authors calculated the cost of
1 month of therapy and divided this by the reduction in mean
monthly migraine frequency to estimate the cost of treatment per
headache prevented. They also estimated the cost-equivalent
number (CEN)—the number of migraines per month at which the
savings in the cost of acute medications would outweigh the cost
of preventive therapy (i.e. the number of migraines per month at
which the preventive therapy would “pay for itself” in reduced
acute treatment costs). This was calculated from the cost of
preventive therapy per month, the percentage reduction in
migraine frequency, and the cost of acute sumatriptan treatment.
The lower the CEN, the more cost effective the preventive
treatment.
For topiramate 200 mg/day, the CEN was 13.7 or 22.5,
depending on whether the cost was based on one 200 mg tablet
or two 100 mg tablets. This compared favorably with gabapentin
2400 mg/day (CEN 24.1), but unfavorably with divalproex sodium
Topiramate | place in therapy review
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Level of
evidence
Design Treatment
and target
dose
[median dose]
Outcome Reference
Paresthesia Anorexia Fatigue Nausea Altered taste Cognitive
difficultya
Withdrawals
due to AEs
2 Pooled
analysis of
2 RCTsg
Placebo
T 50 mg/day
T 100 mg/day
T 200 mg/day
T 100: 48%
Placebo: 6%
T 100: 13%
Placebo: 6%
T 100: 13%
Placebo:
10%
NR NR NR T 50: 17%
T 100: 23%
T 200: 27%
Placebo:
11%
Hart et al.
2003
2 Pooled
analysis of
4 RCTs
Placebo
T 50 mg/day
T 100 mg/day
T 200 mg/day
n=1580 total
Withdrawal:
T: 7%
NR Withdrawal:
T: 4%
Withdrawal:
T: 4%
NR Withdrawal:
T: 3%
NR Lainez et
al. 2003
aDefinitions varied; terms included “language problems,” “memory impairment,” “difficulty with concentration.”
bThe three trials included were Brandes et al. (2004), Silberstein et al. (2004), and Storey et al. (2001).
cMean dose.
dResults refer to a subgroup of patients with migraine with aura, approximately 1/3 of the total.
ePatient numbers unclear in the original as the numbers given in the figures (given here) do not match the numbers given in the text.
fNumber of patients completing the trial. The dropout rate results are given for the number of patients randomized.
gThe two trials were Brandes et al. (2004) and Silberstein et al. (2004).
AE, adverse events; NNH, number needed to harm; NR, not reported; RCT, randomized controlled trial; T, topiramate.Topiramate | place in therapy review
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Level of
evidence
Design Treatment and target dose
[median dose]
Outcome Reference
Patients reporting
weight loss (%)
Mean weight change
2 Double-blind, multicenter RCT,
18 weeks maintenance
Placebo (n=114)
T 50 mg/day
[46.5 mg/day] (n=117)
T 100 mg/day
[85.6 mg/day] (n=120)
T 200 mg/day
[150.2 mg/day] (n=117)
Placebo: 3%
T 50: 6%
T 100: 11%
T 200: 9%
Placebo: increase 0.2%
T 50: decrease 2.2%
T 100: decrease 3.3%
T 200: decrease 4.6%
All T P<0.001 vs placebo
Brandes et al.
2004
2 Double-blind, multicenter RCT,
18 weeks maintenance
Placebo (n=115)
T 50 mg/day
[44.7 mg/day
a] (n=117)
T 100 mg/day
[78.3 mg/day
a] (n=125)
T 200 mg/day
[116.2 mg/day
a] (n=112)
Placebo: 1%
T 50: 5%
T 100: 10%
T 200: 12%
Placebo: increase 0.3%
T 50: decrease 2.4%
T 100: decrease 3.8%
T 200: decrease 3.9%
All T P<0.01 vs placebo
Silberstein et al.
2004
2 Pooled analysis of
2 double-blind single-center
RCTs, 8–12 weeks
maintenance
Placebo (n=36)
T 200 mg/day (n=34)
NR Placebo: No change
T: decrease 5.5 lb 
P=0.0005 T vs placebo
Edwards et al.
2003
2 Multicenter RCT,
7 weeks double-blind followed
by 11 weeks open-label
Placebo (n=115)
T 50 mg/day (n=117)
T 100 mg/day (n=125)
T 200 mg/day (n=112)
b
NR Placebo: increase 0.3%
T 50: decrease 2.4%
T 100 or T 200: decrease 3.8%c
Silberstein 2003
2 Double-blind single-center
RCT, 12 weeks maintenance
Placebo (n=37) 
T 100 mg/day (n=35)d
Placebo: 0
T: 23%
NR Mei et al. 2004
2 Double-blind, single-center
RCT, 8 weeks maintenance
Placebo (n=21)
T 200 mg/day
[125 mg/daya] (n=19)
Placebo: 29%
T: 53%
Placebo: increase 0.55 lb
T: decrease 4.88 lb
P=0.015 T vs placebo
Storey et al. 2001
2 Double-blind multicenter RCT,
18 weeks maintenance
Placebo (n=143)
T 100 mg/day
[87.9 mg/day] (n=139)
T 200 mg/day [124.2 mg/day]
(n=143)
Propranolol 160 [129.6 mg/day]
mg/day (n=143)
Placebo: 1%
T 100: 7%
T 200: 9%
Propranolol: 0%
Placebo: increase 0.6% 
T 100: decrease 2.7%
(P≤0.001 vs placebo)
T 200: decrease 3.4%
(P≤0.001 vs placebo)
Propranolol: increase 2.3%
(P=0.025 vs placebo)
Diener et al. 2004
2 Pooled analysis of
4 RCTs
Placebo
T 50 mg/day
T 100 mg/day
T 200 mg/day
(n=1580 total)
NR Placebo: NR
T 50: decrease 1.8 kg
T 100: decrease 2.5 kg
T 200: decrease 2.8 kgc
Lainez et al. 2003
3 Open survey, mean treatment
duration
7 months
T up to 50 mg/day (n=102) 33% 3–20 kg in 90 days (no mean given) Kowacs et al.
2003
continued opposite…
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1000 mg/day (CEN 9.4) and metoprolol 200 mg/day (CEN 1.2).
The cost per headache prevented showed a similar pattern
($US138 for gabapentin, $US115 or $US67 for topiramate,
$US48 for divalproex sodium, and $US8 for metoprolol)
(Adelman et al. 2002).
However, this study has a number of limitations. First, it included
only the costs of acute and preventive migraine medication, and
did not take account of any other healthcare costs (e.g. visits to
physicians or emergency rooms). There is some evidence that
preventive migraine treatment can reduce such costs (Silberstein
et al. 2003). Second, no account was taken of adverse events,
which vary between the different preventive medications available
and may influence costs. Third, the study did not include indirect
costs, although the authors consider that indirect costs would be
minimal or nonexistent, as their study applies only to patients
demonstrating an excellent response to acute care. Fourth, no
account was taken of rebound headaches. The authors state that
these do not seem to occur with triptan usage limited to no more
than 10 days per month, a value also cited by the BASH
guidelines (BASH 2004), and suggest that for patients
experiencing migraines at higher frequency than this, avoidance
of rebound headache could be an additional benefit of preventive
therapy (Adelman et al. 2002). 
Furthermore, the study pre-dates the publication of three large
RCTs of topiramate in migraine (Brandes et al. 2004; Diener et al.
2004; Silberstein et al. 2004) and a systematic review (Chronicle &
Mulleners 2004). These studies indicated that topiramate
100 mg/day and 200 mg/day appear to have equivalent
effectiveness, which may indicate that the dose of 200 mg/day
used by Adelman et al. (2002) may not be the most appropriate.
Reanalyzing the data using the efficacy results from the large recent
trials and at the 100 mg/dose would provide important evidence.
A more recent cost-effectiveness model using the efficacy data
from the three large randomized placebo-controlled trials and
comparing topiramate 100 mg/day with placebo has been
published in abstract form (Brown et al. 2004). This study included
the cost of preventive therapy, cost of acute treatment, and indirect
costs (time lost from work) for a base-case population of people
who experience a mean of 6 migraine attacks per month in the
absence  of preventive therapy. Topiramate treatment was
associated with a mean reduction of 1.68 migraines per month and
approximately 5 fewer hours lost from work per month, compared
with placebo treatment. The monthly cost of preventive treatment
with topiramate 100 mg/day was $US113, which was partially
offset by savings in the cost of acute treatment ($US25) and in the
cost of time off work ($US46). Thus, the net cost of preventive
treatment with topiramate 100 mg/day was estimated at
approximately $US42 per month, and the net cost per migraine
avoided was $US26 (Brown et al. 2004). For populations with a
higher baseline migraine frequency the cost effectiveness
improved, and in patients with 10 migraines per month the model
predicted that topiramate 100 mg would be cost saving (Brown et
al. 2004). These findings need to be confirmed by results from
direct observation.
Resource utilization
The acquisition price of topiramate is higher than some alternative
migraine preventive therapies; for example, in the USA the cost of
30 days’ treatment with topiramate 100 mg/day has been
estimated at $US203, compared with $US31 for generic
propranolol, $US73 for divalproex sodium (Depakote®), and $US4
for generic amitriptyline (Anon. 2005b). Widespread use of
topiramate for migraine prevention may therefore be expected to
increase medication costs.
Successful migraine prophylaxis could have the potential to reduce
usage of other healthcare resources. This has been investigated in
a claims data analysis of the health insurance records of 366 US
patients receiving acute and preventive treatment for migraine
(Silberstein et al. 2003). Physician visits for migraine decreased by
Topiramate | place in therapy review
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…table continued
Level of
evidence
Design Treatment and target dose
[median dose]
Outcome Reference
Patients reporting
weight loss (%)
Mean weight change
3 Retrospective case
series, mean treatment
duration 149 days 
T mean dose 208 mg/day (n=74)
Topiramate treatment period
compared with previous
treatment
NR Decrease 3.1 kg (3.8%) Young et al. 2002
3 Open-label longitudinal
single-center study,
134 patients assessed
after 3 months of
topiramate treatment
T titrated up to 100 mg/day
target dose
78% Decrease 3.44 kg Krymchantowski
& Tavares 2004
aMean dose.
bPatient numbers unclear in the original as the numbers given in the figures (given here) do not match the numbers given in the text.
cNo between-group comparison reported.
dPatients who completed the trial.
ITT, intention-to-treat; NR, not reported; NSD, not statistically significantly different; RCT, randomized controlled trial; T, topiramate.51% and emergency room visits for migraine decreased by 82% in
the second 6 months after the migraine preventive medication was
first prescribed compared with the 6 months before (Silberstein et
al. 2003). However, there has been some debate about the
methods used by this study and its conclusions (Adelman et al.
2003). No specific evidence relating to the potential effect of
topiramate on healthcare resources was identified. 
As indirect costs are a major component of the total cost of
migraine (see Disease overview section), successful migraine
prevention could theoretically reduce the number of days on
which patients are partly or entirely disabled by migraine.
Evidence from one double-blind placebo-controlled trial reported
that topiramate 100 mg/day reduced the mean monthly number
of days with disability by approximately 4.2 after 16 weeks of
treatment, compared with a reduction of approximately 1 with
placebo (Mei et al. 2004). Furthermore, a cost-effectiveness
modeling study estimated that topiramate 100 mg/day was
associated with a saving of US$46 per patient per month in the
cost of lost work time in a population with a baseline migraine
frequency of 6 migraines/month, partly offsetting the additional
cost of topiramate (Brown et al. 2004). This evidence indicates
that topiramate has the potential to reduce time away from work
or normal activities due to migraine, thereby reducing indirect
costs, but direct evidence is needed to assess this possibility. No
evidence was identified comparing topiramate with other
preventive migraine treatments on this issue.
Topiramate has been shown to improve HRQOL relative to
placebo, especially at doses of 100 or 200 mg/day (Diamond et
al. 2003). However, there was no evidence comparing the
effects of topiramate on HRQOL with that of other migraine
prophylactic treatments. No cost–utility study has been
published estimating the potential effect of topiramate on
quality-adjusted life-years (QALYs). 
Weight gain may be an important cause of treatment
discontinuation (Von Seggern 2002). Several preventive migraine
treatments are typically associated with weight gain, such as
propranolol, amitriptyline, and divalproex sodium. In contrast,
topiramate may be associated with weight loss rather than weight
gain, which some patients may prefer. This in turn may help to
encourage better adherence to therapy and consequently better
effectiveness. However, no evidence is available on this point.
Further economic studies comparing topiramate with other widely
used migraine preventive treatments (e.g. propranolol) and including
a wider range of costs and outcomes are required for a full evaluation
of the cost effectiveness of topiramate in migraine prevention.
Patient group/population
Treatment guidelines recommend that preventive therapy should
be considered in patients with migraine that is severe and/or
frequent enough to interfere with daily life, patients with overuse
of acute therapy, and patients with an inadequate response to
acute therapy (see Table 4). A treatment trial period of at least 2–3
months is generally recommended for preventive therapy
(Silberstein 2000; Snow et al. 2002), though the optimum duration
of treatment is uncertain (Evans 2004).
As reviewed in the Clinical evidence section, topiramate has
demonstrated greater effectiveness than placebo in reducing
migraine frequency in several RCTs. Patients recruited to these
trials typically had a diagnosis of migraine by IHS criteria, had
experienced migraine attacks for at least 6 months or at least 1
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Design and patients Treatment Results Reference
Observational study in patients with
>1 migraine/week, who had not responded
to or tolerated beta blockers, amitriptyline,
flunarizine, and/or valproate (n=115)
Topiramate (most common dose
100 mg/day) for 3 months
56% responded (reduction in migraine
frequency >50%)
Pascual et al. 2003
Retrospective chart review of patients with
transformed migraine (n=96)
Add-on topiramate (mean dose
87.5 mg/day), mean follow-up
8.4 monthsa
Reduction in mean migraine frequency,
mean severity, mean headache days/month,
mean MIDAS score and rescue medication
use vs baseline (P<0.01)
Mathew et al. 2002
Retrospective chart review of patients who
had not responded to a median of 9
preventive migraine medications (n=69)
Topiramate (median dose 100 mg/day),
median follow-up 12 weeks
49 of 69 patients took additional preventive
therapy
Reduction in mean 28-day frequency of
moderate/severe migraines vs baseline
(P=0.0004).
NSD vs baseline for frequency of mild
headaches
Von Seggern et al. 2002
Uncontrolled trial in patients with >3
migraines/month, 80% were taking
propranolol and/or flunarizine (n=36)
Add-on topiramate (up to 100 mg/day) for
3 months
Reduction in mean migraine frequency,
duration and intensity vs baseline
(P<0.001)
Martinéz et al. 2003
Uncontrolled trial in patients with high
frequency migraine refractory to other
prophylactic drugs (n=7)
Topiramate 100 mg/day for 12 weeks
maintenance
Reduction in mean number of days with
migraine vs baseline (P=0.0036)
Tonini et al. 2003
aFor all patients in the study, including patients with episodic migraine (n=70) and cluster headache (n=12).
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year, and had a frequency of migraine attacks of at least two per
month (Storey et al. 2001; Edwards et al. 2003), 2–6 per month
(Mei et al. 2004), or 3–12 per month (Brandes et al. 2004; Diener
et al. 2004; Silberstein et al. 2004), but no more than 15 migraine
days per month (Brandes et al. 2004; Diener et al. 2004). The
frequency of migraines in the population in the RCTs
corresponds broadly to the frequency considered an indication
for preventive treatment in the US guidelines (Snow et al. 2002;
see Table 4). Thus, the evidence on effectiveness and tolerability
of topiramate reviewed above can be considered relevant to the
general population of patients eligible for preventive migraine
treatment. Further evidence relating to specific population
groups is reviewed below.
Refractory and transformed migraine
Topiramate has been shown to be effective, either as
monotherapy or as add-on therapy, in patients with
transformed migraine and/or migraine refractory to previous
preventive therapy in several retrospective, uncontrolled, and
observational studies (Table 10). Evidence from RCTs is
required to confirm the effects of topiramate in this patient
group.
Migraine with vertigo
Carmona and Settecase (2005) reported an open trial of
topiramate (average dose 100 mg/day) in 10 patients with
migraine and vertigo. At the time of publication, the authors
reported that only two of 10 patients had experienced a
migraine crisis during the treatment period (range 6–16 months,
mean 9 months).
Cost effectiveness in different patient populations
It has been suggested that antiepileptic drugs (including
topiramate) are likely to demonstrate greater clinical and
economic value in patients who experience >10 migraines/month
than in patients with less frequent migraine (Adelman et al. 2002).
The recommendation appears to be derived in part from the
authors’ calculations of cost-equivalent number (see Economic
evidence section) and partly because headache rebound “does
not seem to occur with [triptan] use limited to 10 days/month or
less” (Adelman et al. 2002). However, it is consistent with results
from a cost-effectiveness model utilizing efficacy data from three
large randomized double-blind studies and US unit costs (Brown
et al. 2004). This model indicated that topiramate 100 mg/day
would be cost saving in patients who experience 10
migraines/month in the absence of preventive therapy (Brown et
al. 2004). Further direct evidence is needed to evaluate the
frequency threshold at which topiramate and other preventive
therapies become cost effective.
Dosage, administration, and formulations
Topiramate (Topamax®) is indicated for the prophylaxis of
migraine in adults (Anon. 2005a). It is available as coated tablets
containing 25 mg, 50 mg, 100 mg, or 200 mg topiramate, and as
sprinkle capsules containing 15 mg or 25 mg topiramate. The
sprinkle capsules may be taken as whole capsules or opened and
the granular contents sprinkled onto a teaspoon of soft food
which should then be eaten immediately (Anon. 2005a).
The recommended total daily dose for topiramate in migraine
prevention is 100 mg/day administered in two divided doses. The
dose should be titrated gradually as follows: week 1, 25 mg in
the evening; week 2, 25 mg morning and evening; week 3, 50 mg
in the evening and 25 mg in the morning; and week 4, 50 mg
morning and evening. In patients with renal impairment
(creatinine clearance <70 mL/min/1.73 m2) the dose should be
adjusted to half the normal adult dose. Topiramate is cleared by
hemodialysis 4–6 times faster than its clearance in a healthy
individual, so in patients undergoing hemodialysis a
supplemental dose of topiramate may be required to maintain a
steady-state topiramate plasma concentration. The dose
adjustment depends on the duration and clearance rate of the
dialysis and the effective renal clearance of topiramate in the
patient being dialyzed (Anon. 2005a).
Place in therapy
The evidence summary table at the beginning of this article
summarizes the evidence published on topiramate in the
preventive treatment of migraine. All the outcome measures
reported were considered to be patient-oriented rather than
disease-oriented, as they measured endpoints such as a
reduction in migraine frequency or severity that are of clear
benefit to the patient. Most evidence concentrated on measures
specific to migraine (e.g. attack frequency), though a few studies
attempted to assess the broader impact of migraine on patients’
lives by measuring disability or HRQOL. 
All the comparative trials were placebo-controlled and 
powered only for the comparison of topiramate with placebo.
One (Diener et al. 2004) included a propranolol group as an
active control. Although not powered to compare the two 
active treatments, this trial is at present the only evidence 
of the efficacy and tolerability of topiramate in relation to
existing preventive migraine treatment. Since it is probably
unlikely that a patient requesting preventive therapy for 
frequent and/or disabling migraine would be sent away 
with no treatment, the placebo-controlled trials do not represent
a treatment choice (topiramate or no treatment) that is 
likely to be widespread in current practice. Comparative trials
against current first-line preventive therapies will be required to
change practice in the general population of patients 
needing preventive migraine treatment. In the population of
patients with migraine refractory to existing therapies, the
limited evidence available suggests that topiramate may be
effective in some patients where existing treatments have 
failed or have not been tolerated. Although limited, this 
evidence may guide practice to consider a trial of topiramate in
such patients. 
Substantial evidence from pooled analyses of RCTs suggests a
positive effect for topiramate on HRQOL compared with placebo.
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to reduce disability due to migraine, but this needs to be
confirmed by further trials.
Clear evidence from randomized controlled trials powered on
this endpoint has demonstrated that topiramate 100 mg/day 
or 200 mg/day is more effective than placebo in reducing 
the mean monthly frequency of migraines. A systematic 
review and meta analysis compared the doses and found 
that 100 mg/day and 200 mg/day were not significantly different
in efficacy, and that both were significantly superior 
to 50 mg/day. 
This pattern is supported by evidence from secondary efficacy
endpoints in RCTs (responder rate, mean number of migraine
days/month, rescue medication use, migraine severity, and
migraine duration). One RCT reported that 200 mg/day was less
effective than 100 mg/day (Diener et al. 2004), but the authors
consider that this paradoxical result may reflect the high rate of
early dropouts due to adverse events observed in the
200 mg/day group. Some evidence from uncontrolled studies
indicates that topiramate (either alone or as add-on therapy)
may be effective in patients who have previously failed to
respond to, or have not tolerated, other preventive migraine
therapies. This observation requires confirmation by RCTs in this
patient population.
There have been no trials published that were powered to
compare topiramate with alternative treatments for prevention
of migraine. One large RCT used propranolol 160 mg/day as 
an active control, but this trial was powered only to compare
between active treatment and placebo and the authors 
stress that comparing between topiramate and propranolol as
well would have required a larger sample size (Diener et al.
2004). Nevertheless, this trial found that topiramate 100 mg/day
and propranolol 160 mg/day appeared to have broadly
comparable efficacy and tolerability. As the two agents have
different adverse event profiles and contraindications, the
authors concluded that either drug could be used in cases
where the other is contraindicated or not tolerated (Diener et al.
2004). This seems a fair conclusion from the current limited
evidence base. Further evidence from true comparative trials is
required to assess the therapeutic value of topiramate relative 
to other agents.
The main adverse events associated with topiramate appear to
be central nervous system effects such as paresthesia, altered
taste, and cognitive problems. These have been consistently
reported at a higher rate than with placebo in RCTs, and appear
to occur more frequently at the 200 mg/day dose than the
100 mg/day dose. Since it has been reported that the
100 mg/day and 200 mg/day doses have similar efficacy, the
overall evidence suggests that 100 mg/day may provide the
best balance between efficacy and tolerability. This was the
conclusion drawn by Diener et al. (2004). However, the optimum
dose will vary between individual patients, and an uncontrolled
survey has reported efficacy at doses of 50 mg/day and below
(Kowacs et al. 2003).
Strong evidence from several trials, with no published
contradictory evidence, shows that topiramate is associated with
weight loss. The mean weight loss reported has typically been
around 2–3 kg or 3–4% of baseline body weight over observation
periods typically of a few months. As weight gain is common with
other preventive migraine therapies, and has been suggested as
a major reason for discontinuation of treatment, the occurrence
of weight loss with topiramate may be considered advantageous
by some patients. It may help to encourage adherence to
therapy, although published evidence is lacking on this point.
However, it is not clear from the current evidence base whether
weight loss continues during long-term treatment or whether it
reaches a plateau. Information is needed on this issue to
determine whether topiramate-associated weight loss is likely to
be a benefit or a drawback.
Very little economic evidence has been published on
topiramate in migraine prevention. The sole fully published
study compared topiramate, gabapentin, divalproex sodium,
and metoprolol in terms of their cost per headache avoided and
the number of migraines required per month for each drug to
pay for itself in reduced expenditure on acute medication
(Adelman et al. 2002). However, this study considered only a
limited range of costs, used data from a small study that pre-
dated the recent large randomized trials, and used a relatively
high topiramate dose of 200 mg/day. Updating the study with
more recent data and investigating the 100 mg/day dose
(which, as discussed above, seems to be emerging as the likely
preferred dose on the current evidence base) could be valuable.
This has been addressed by a modeling study using data on
topiramate 100 mg/day from three randomized controlled trials,
which found that savings in time lost from work and the cost of
acute treatment partially offset the cost of topiramate treatment
(Brown et al. 2004). In patients who experience 10 migraines
per month in the absence of preventive treatment, this study
suggested that topiramate 100 mg/day would be cost saving.
However, further economic studies on a wider range of costs
and outcomes and in comparison with other widely-used
agents are required to evaluate the cost effectiveness of
topiramate in migraine prophylaxis.
In summary, the current evidence base suggests that
topiramate is more effective than placebo in migraine
prevention and that a dose of 100 mg/day is likely to offer the
best balance between efficacy and tolerability (though the
optimum dose will vary between individual patients). The
limited evidence available indicates that topiramate
100 mg/day may be broadly comparable to propranolol
160 mg/day. Weight loss may be expected to occur with
topiramate treatment, rather than weight gain, and this may be
an important consideration for some patients. As generic
propranolol has a considerably lower acquisition cost than
topiramate, propranolol is likely to remain first-line therapy in
patients in whom it is well tolerated, effective, and not
contraindicated. For patients in whom propranolol or other
preventive migraine therapies are contraindicated, poorly
tolerated, or have been found ineffective, topiramate is a
valuable therapeutic option. 
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